Eli Lilly reported a 56% year-over-year revenue increase in Q1 2026, fueled by strong sales of obesity drug MOUNJARO ($8.66B, +125%) and diabetes drug ZEPBOUND ($4.16B, +80%). The company’s pipeline shows promising progress with the launch of FOUNDAYO and advancements in Retatrutide and Eloralintide. Double-digit growth in EBGLYSS and JAYPIRCA, along with upcoming label expansions, support a $2 billion increase in full-year 2026 revenue guidance. Analyst Terry Chrisomalis maintains a 'strong buy' rating, citing robust growth and multiple near-term clinical and regulatory milestones.
Amplia Therapeutics has entered a clinical collaboration with Eli Lilly to test their drug narmafotinib combined with Lilly's KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer (NSCLC) patients. The Phase 1b/2b trial will evaluate ...
Amplia Therapeutics has signed a collaboration agreement with Eli Lilly to evaluate a combination of Amplia’s investigational FAK inhibitor, narmafotinib, with Lilly’s KRAS G12C inhibitor, olomorasib, in a Phase 1b/2b trial for advanced non-small cel...
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
Eli Lilly's investigational drug olomorasib received FDA Breakthrough Therapy designation for treating advanced pancreatic cancer patients with the KRAS G12C mutation who have had prior systemic therapy. This designation aims to speed up development ...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
